Results 41 to 50 of about 350,390 (302)

Plitidepsin: a Repurposed Drug for the Treatment of COVID-19

Antimicrobial Agents and Chemotherapy, 2021
Finding antivirals to reduce coronavirus disease 2019 (COVID-19) morbidity and mortality has been challenging. Large randomized clinical trials that aimed to test four repurposed drugs, hydroxychloroquine, lopinavir-ritonavir, interferon beta 1a, and remdesivir, have shown that these compounds lack an impact on the COVID-19 course.
openaire   +3 more sources

Clinical trials on drug repositioning for COVID-19 treatment [PDF]

Revista Panamericana de Salud Pública, 2020
The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genusBetacoronavirus, that is distributed in birds, humans, and other mammals.
Sandro G. Viveiros Rosa, Wilson C. Santos   +1 more
openaire   +3 more sources

Treatments for COVID-19: emerging drugs against the coronavirus.

Acta bio-medica : Atenei Parmensis, 2020
The Coronavirus disease 19 (COVID-19) outbreak has been recognized as a global threat to public health. It is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and no effective therapies currently exist against this novel viral agent.
Potì, Francesco, Pozzoli, Cristina, Adami, Maristella, Poli, Enzo, Costa, Lucio G   +4 more
openaire   +5 more sources

Drug interactions of ivermectin with a focus on COVID-19 treatment

Muller Journal of Medical Sciences and Research, 2021
Treatment of COVID-19 largely depends on previously used drugs as there is no cure available coupled with shortage of effective vaccine with doubts about its long-term protection due to rapid viral mutations.
Padmaja Udaykumar, Bhavya Shetty, Anurag Kundapur   +2 more
doaj   +1 more source

Liver drug damage: possibilities of polyionic succinate-methioninic complex during the pandemic of new coronavirus infection (COVID-19)

Медицинский совет, 2021
Medicinal liver damage is an important problem not only in the framework of hepatology and gastroenterology, but also for internal medicine in  general, which is due to the  difficulties of  correct and timely diagnosis of  this pathology. In  the  first
D. I. Trukhan, E. L. Davydov
doaj   +1 more source

Local guidelines for drug treatment of patients with COVID-19 [PDF]

Medicinski casopis, 2020
Objective. Until now, there have been no guidelines for the use of drugs in patients with COVID 19 in the Republic of Serbia that have been authorized and published in the professional or scientific literature, or on the official websites of the Ministry of Health or healthcare institutions. The aim of this paper is to present a local guideline for the
Slobodan Janković, Katarina Pavlović, Vladimir Vukićević, Jagoda Gavrilović, Marko Folić, Predrag Čanović, Ružica Marjanović, Slavica Mojsilović, Nebojša Stevanović, Nikola Rosić   +9 more
openaire   +2 more sources

Antiviral Drug Discovery for the Treatment of COVID-19 Infections

Viruses, 2022
The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently emerged human coronavirus. COVID-19 vaccines have proven to be successful in protecting the vaccinated from infection, reducing the severity of disease, and deterring the transmission of infection. However, COVID-19
Teresa I. Ng, Ivan Correia, Jane Seagal, David A. DeGoey, Michael R. Schrimpf, David J. Hardee, Elizabeth L. Noey, Warren M. Kati   +7 more
openaire   +3 more sources

Drug Repurposing for the Treatment of COVID‐19: A Knowledge Graph Approach [PDF]

Advanced Therapeutics, 2021
Identifying effective drug treatments for COVID‐19 is essential to reduce morbidity and mortality. Although a number of existing drugs have been proposed as potential COVID‐19 treatments, effective data platforms and algorithms to prioritize drug candidates for evaluation and application of knowledge graph for ...
Vincent K. C. Yan, Xiaodong Li, Xuxiao Ye, Min Ou, Ruibang Luo, Qingpeng Zhang, Bo Tang, Benjamin J. Cowling, Ivan Hung, Chung Wah Siu, Ian C. K. Wong, Reynold C. K. Cheng, Esther W. Chan   +12 more
openaire   +4 more sources

Protease inhibitors targeting coronavirus and filovirus entry. [PDF]

, 2015
In order to gain entry into cells, diverse viruses, including Ebola virus, SARS-coronavirus and the emerging MERS-coronavirus, depend on activation of their envelope glycoproteins by host cell proteases.
Agudelo, Juliet, Barnard, Dale, Carrion, Ricardo, Lu, Kai, McKerrow, James H, Nunneley, Jerritt W, Pöhlmann, Stefan, Renslo, Adam R, Simmons, Graham, Vedantham, Punitha, Zhou, Yanchen   +10 more
core   +1 more source

Old and re-purposed drugs for the treatment of COVID-19 [PDF]

Expert Review of Anti-infective Therapy, 2020
Introduction: The coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed since December 2019. It has caused a global pandemic with more than three hundred thousand case fatalities.
Jean, Shio-Shin, Hsueh, Po-Ren
openaire   +2 more sources